Adaptimmune Limited

Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients

Read More

Click here to see our Second Quarter 2019 Financial Results and Business Update

Click Here

Adaptimmune announces start of SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS

Read More

You can find new videos about our SPEAR T-cells

Learn More

Explore stories from our colleagues and external experts on our science and how we're working to improve patient lives by transforming cancer treatment

Click Here

Focusing on the needs of our patients

Learn More

Latest News • View all

September 9, 2019
United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4
August 27, 2019
Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients
August 1, 2019
Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update

Adaptimmune on Linkedin linkedin

Adaptimmune on Twitter

Clinical Trials
Clinical Trials
Our Pipeline
Our Pipeline
Manufacturing
Manufacturing
Partnerships
Partnerships
Perspectives
Perspectives